Sunday, June 4, 2023, Chicago, Illinois, 6:45 AM – 7:45 AM Central Time (7:45 AM – 8:45 AM Eastern Time)

Breakfast with the Investigators: Ovarian Cancer

A CME Hybrid Symposium Held in Conjunction with the 2023 ASCO Annual Meeting

Location
Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Phone: (312) 922-4400

Program Schedule — Central Time
6:15 AM – 6:45 AM — Registration and Breakfast
6:45 AM – 7:45 AM — Educational Meeting

Meeting Room
Grand Ballroom (Level 2)


This event will also be webcast live.
Please see Registration tab for details.
There is no registration fee for this event. For the in-person symposium in Chicago, preregistration is required as seating is limited.  
 
Faculty
Philipp Harter, MD, PhD
Gynecologic Oncologist
Director at the Department of Gynecology
and Gynecologic Oncology
Evang Kliniken Essen-Mitte
Essen, Germany

David M O'Malley, MD
Professor
Division Director, Gynecologic Oncology
The Ohio State University and The James Cancer Center
Columbus, Ohio


Shannon N Westin, MD, MPH
Professor
Medical Director, Gynecologic Oncology Center
Director, Early Drug Development
Department of Gynecologic Oncology
and Reproductive Medicine
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Moderator
Neil Love, MD
Research To Practice
Miami, Florida


This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, GSK, Merck, Mersana Therapeutics Inc, and Novocure Inc.
Program Schedule — Central Time
6:15 AM – 6:45 AM — Registration and Breakfast Buffet
6:45 AM – 7:45 AM — Educational Meeting

MODULE 1: Up-Front Treatment for Advanced Ovarian Cancer (OC)

  • Incidence of germline and somatic BRCA mutations and homologous recombination deficiency among patients with advanced OC; indications and optimal platforms for genetic testing
  • Long-term outcomes with olaparib, niraparib or olaparib/bevacizumab maintenance therapy for patients with newly diagnosed OC
  • Optimal integration of up-front PARP inhibitor maintenance; use of clinical characteristics and other factors to select among olaparib, niraparib and olaparib/bevacizumab
  • Key efficacy and safety findings with maintenance niraparib/bevacizumab after front-line platinum-based chemotherapy and bevacizumab for patients with advanced OC in the Phase II OVARIO trial
  • Recommended starting dose and duration of treatment with approved PARP inhibitors in the front-line maintenance setting

MODULE 2: The Evolving Management Paradigm for Relapsed/Refractory (R/R) OC

  • Clinical, biological and patient-specific factors in the selection and sequencing of treatment for R/R advanced OC
  • Relevance of repeat genetic testing for patients with R/R OC; incidence of BRCA reversion mutations and effect on response to chemotherapy and PARP inhibition
  • Significance of overall survival findings from studies evaluating PARP inhibitors as later-line therapy for advanced OC; rationale for the voluntary withdrawal of various PARP inhibitor indications in the relapsed setting
  • Utility of PARP inhibitor rechallenge for patients who have experienced disease progression on a previous PARP inhibitor
  • Biological rationale for targeting folate receptor alpha in patients with OC; mechanism of action of mirvetuximab soravtansine
  • Available efficacy and safety data with mirvetuximab soravtansine for patients with folate receptor alpha-positive, platinum-resistant OC
  • Recent FDA approval of mirvetuximab soravtansine; implications for biomarker assessment and current OC management

MODULE 3: Novel Agents and Strategies Under Investigation for Advanced OC

  • Biological rationale for combining PARP inhibitors with immune checkpoint inhibitors for patients with advanced OC
  • Emerging results from the Phase III DUO-O study of up-front durvalumab in combination with chemotherapy and bevacizumab followed by durvalumab, olaparib and bevacizumab as maintenance therapy; implications for clinical practice and ongoing research
  • Other ongoing Phase III trials investigating the utility of front-line PARP inhibitors with immunotherapy for advanced OC (eg, ATHENA-COMBO, FIRST)
  • Biological rationale for targeting the sodium-dependent phosphate transport protein NaPi2b in OC; mechanism of action of upifitamab rilsodotin (UpRi)
  • Available efficacy and safety data with and ongoing investigation of UpRi for patients with OC
  • Mechanism of action of tumor treating fields and biological rationale for their investigation in OC
  • Early-phase efficacy and safety data with and ongoing investigation of tumor treating fields in combination with chemotherapy for advanced OC
  • Other novel agents and strategies under investigation for OC

Target Audience
This activity is intended for medical and gynecologic oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of ovarian cancer (OC).

Learning Objectives
Upon completion of this activity, participants should be able to

  • Consider available clinical research findings with PARP inhibitors as maintenance therapy after first-line platinum-based chemotherapy for advanced OC, and counsel appropriate patients regarding personalized treatment recommendations.
  • Assess available clinical trial data with and newly adapted indications for FDA-endorsed PARP inhibitors for recurrent OC in order to appropriately incorporate these agents into current management algorithms.
  • Evaluate the biologic rationale for and published and emerging clinical research with PARP inhibitors in combination with other systemic therapies, and consider the potential clinical and research implications of these findings for OC management.
  • Recognize the rationale for targeting folate receptor alpha in OC, and determine optimal methods to test for, and the current role of novel approaches to therapeutically exploit, this newly relevant biomarker.
  • Appreciate the incidence of sodium-dependent phosphate transport protein 2b expression in OC, and evaluate published research with and ongoing clinical trials assessing investigational agents designed to exploit this potential therapeutic target.
  • Describe the scientific rationale for the use of tumor treating fields as a therapeutic approach for patients with OC, and appraise the available efficacy and safety data with this strategy in combination with chemotherapy for recurrent, advanced disease.
  • Recall the design of ongoing clinical trials evaluating novel agents and strategies for OC, and counsel appropriate patients about availability and participation.

CME Credit Form
A CME credit form will be given to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr Harter — Advisory Committee: AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, GSK, ImmunoGen Inc, Merck Sharp & Dohme LLC, Mersana Therapeutics Inc, Miltenyi Biotec, Novartis, Roche Laboratories Inc; Consulting Agreement: Exscientia; Contracted Research: AstraZeneca Pharmaceuticals LP, Clovis Oncology, Genmab US Inc, GSK, ImmunoGen Inc, Novartis, Roche Laboratories Inc, Seagen Inc; Travel Support: AstraZeneca Pharmaceuticals LP. Dr O'Malley — Advisory Committee and Consulting Agreements (Personal Fees): AbbVie Inc, Adaptimmune, Agenus Inc, Arcus Biosciences, Arquer Diagnostics, AstraZeneca Pharmaceuticals LP, Atossa Therapeutics, Cardiff Oncology, Celcuity, Clovis Oncology, Corcept Therapeutics, Duality Biologics, Eisai Inc, Elevar Therapeutics, Exelixis Inc, F Hoffmann-La Roche Ltd, Genelux Corporation, Genentech, a member of the Roche Group, GSK, ImmunoGen Inc, Imvax Inc, InterVenn Biosciences, InxMed, Iovance Biotherapeutics, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Laekna Therapeutics, Leap Therapeutics Inc, Luzsana Biotechnology, Merck, Merck Sharp & Dohme LLC, Mersana Therapeutics Inc, Myriad Genetic Laboratories Inc, Novartis, Novocure Inc, OncoC4, Onconova Therapeutics Inc, R-Pharm, Regeneron Pharmaceuticals Inc, Replimune, Roche Diagnostics, Seagen Inc, Sorrento Therapeutics, Sumitomo Dainippon Pharma Oncology Inc, Sutro Biopharma, Tarveda Therapeutics, Toray Industries Inc, Trillium Therapeutics Inc, Umoja Biopharma, VBL Therapeutics, Verastem Inc, Vincerx Pharma, Xencor, Zentalis Pharmaceuticals; Contracted Research (Institution Received Funds): AbbVie Inc, Advaxis Inc, Agenus Inc, Alkermes, Aravive Inc, Arcus Biosciences, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol Myers Squibb, Clovis Oncology, Deciphera Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, F Hoffmann-La Roche Ltd, Genentech, a member of the Roche Group, Genmab US Inc, GSK, ImmunoGen Inc, Incyte Corporation, Iovance Biotherapeutics, Karyopharm Therapeutics, Leap Therapeutics Inc, Merck, Merck Sharp & Dohme LLC, Mersana Therapeutics Inc, Novartis, Novocure Inc, OncoC4, OncoQuest Inc, Pfizer Inc, Predictive Oncology Inc, Prelude Therapeutics, Regeneron Pharmaceuticals Inc, Rubius Therapeutics, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Sutro Biopharma, Tesaro, A GSK Company, Verastem Inc; Nonrelevant Financial Relationship: GOG Foundation Inc, Ludwig Institute for Cancer Research Ltd, National Cancer Institute, NRG Oncology, RTOG, SWOG. Dr Westin — Consulting Agreements: AstraZeneca Pharmaceuticals LP, Caris Life Sciences, Clovis Oncology, Eisai Inc, EQRx, Genentech, a member of the Roche Group, Gilead Sciences Inc, GSK, ImmunoGen Inc, Lilly, Merck, Mereo BioPharma, Mersana Therapeutics Inc, NGM Biopharmaceuticals, Nuvectis Pharma Inc, Seagen Inc, Verastem Inc, Vincerx Pharma, Zentalis Pharmaceuticals, ZielBio; Contracted Research: AstraZeneca Pharmaceuticals LP, Avenge Bio, Bayer HealthCare Pharmaceuticals, Bio-Path Holdings, Clovis Oncology, Genentech, a member of the Roche Group, GSK, Mereo BioPharma, Novartis, Zentalis Pharmaceuticals.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.

Research To Practice CME Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, GSK, Merck, Mersana Therapeutics Inc, and Novocure Inc.

Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Phone: (312) 922-4400

Meeting Room
Grand Ballroom (Level 2)

Directions
The Hilton Chicago hotel is located just 5 minutes (2.5 miles) north of the McCormick Place convention center, where the ASCO Annual Meeting is taking place.

 
This activity is intended for medical and radiation oncologists, gynecologic oncologists, hematologists, hematology-oncology fellows and other healthcare providers involved in the treatment of ovarian cancer.

​ ​ ​
IN-PERSON registration
Thank you for your interest in our CME program taking place in Chicago, IL. At this time online in-person preregistration is closed for this event. SEATS ARE STILL AVAILABLE FOR THE PROGRAM AND WILL BE OFFERED ON A FIRST COME FIRST SERVCE BASIS. Our Onsite Registration Desk will be open at 6:15 AM Central Time on Sunday, June 4. If you are interested in attending, please visit our registration desk located outside the Grand Ballroom (Level 2) of the Hilton Chicago hotel (720 South Michigan Avenue). ASCO offers complimentary shuttle service from the McCormick Place Convention Center to this hotel. Information on shuttle service is available on the 2023 ASCO Annual Meeting website. Please note: onsite registration does not guarantee meal service which will be based on availability.

If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153.

Registration for live webcast

Please note we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.

Registration for Webcast »

Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk at least 30 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.

 

Not an official event of the 2023 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, Association for Clinical Oncology, CancerLinQ®, or Conquer Cancer®, the ASCO Foundation.